<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments; Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments; Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2024-10-18 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA." This guidance provides information and recommendations on the Generic Drug User Fee Amendments (GDUFA) III program enhancements agreed upon by the Agency and industry in "GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027" (GDUFA III commitment letter), relat...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2024-24104</p>
    <p><strong>Publication Date:</strong> 2024-10-18</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2024/10/18/2024-24104/review-of-drug-master-files-in-advance-of-certain-abbreviated-new-drug-application-submissions-under">https://www.federalregister.gov/documents/2024/10/18/2024-24104/review-of-drug-master-files-in-advance-of-certain-abbreviated-new-drug-application-submissions-under</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2024-24104</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
